World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 20 February 2023
Main ID:  NCT04121780
Date of registration: 25/09/2019
Prospective Registration: Yes
Primary sponsor: Center for Neurological Studies
Public title: Growth Hormone Replacement Therapy for Retried Professional Football Players
Scientific title: Interventional Study of Growth Hormone Replacement Therapy in Retired Professional Football Players With Growth Hormone Deficiency
Date of first enrolment: October 8, 2019
Target sample size: 42
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/show/NCT04121780
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).  
Phase:  Phase 2
Countries of recruitment
United States
Contacts
Name:     Randall R Benson, MD
Address: 
Telephone:
Email:
Affiliation:  Vice President and Medical Director
Name:     Vijay M Baragi, Ph.D.
Address: 
Telephone: 313-228-0930.
Email: vijay@neurologicstudies.com
Affiliation: 
Name:     Vijay Baragi, Ph.D.
Address: 
Telephone: 313-228-0930
Email: vijay@neurologicstudies.com
Affiliation: 
Key inclusion & exclusion criteria

Inclusion Criteria:

- The subject is willing to provide a signed and dated informed consent indicating that
he understands the purpose and procedures required for the study and is willing to
participate in the study.

- Former NFL player

- At least one year since retirement from football

- Less than 76 years of age

- Diagnosis of GHD on clinical grounds by a neurologist and an endocrinologist GHD

Exclusion Criteria:

- History of pre-existing brain disease other than concussion or TBI

- History of a premorbid disabling condition that interferes with outcome assessments

- Contraindication to GH therapy

- Type I and II Diabetes mellitus

- Active malignant disease

- Acute critical illness, heart failure, or acute respiratory failure

- Subjects who are deficient in cortisol, testosterone or thyroid at screening will be
excluded until hormone abnormalities have been corrected.



Age minimum: 18 Years
Age maximum: 76 Years
Gender: Male
Health Condition(s) or Problem(s) studied
TBI (Traumatic Brain Injury)
Concussion, Brain
Anterior Pituitary Hyposecretion Syndrome
Hypopituitarism
Growth Hormone Deficiency
Sport Injury
Intervention(s)
Other: Placebo
Biological: Growth Hormone
Primary Outcome(s)
Cognitive functions- ANAM ( Automated Psychological Assessment Metrics) [Time Frame: From baseline to 1-year post-treatment]
Cognitive functions- Verbal learning and memory [Time Frame: From baseline to 1-year post-treatment]
Cognitive functions- Working Memory [Time Frame: From baseline to 1-year post-treatment]
Cognitive functions- Processing Speed [Time Frame: From baseline to 1-year post-treatment]
Cognitive functions- Executive Function. [Time Frame: From baseline to 1-year post-treatment]
Secondary Outcome(s)
Change in Physical function- Peak O2 consumption (Vo2 max) [Time Frame: One year (from baseline to 1-year post-treatment)]
Change in QEEG Markers- power spectra [Time Frame: One year (from baseline to 1-year post-treatment)]
Change in Physical function- Isokinetic knee extension peak torque [Time Frame: One year (from baseline to 1-year post-treatment)]
Adverse events [Time Frame: One year (from baseline to 1-year post-treatment)]
MRI [Time Frame: One year (from baseline to 1-year post-treatment)]
Change in QEEG Markers- Connectivity Measures [Time Frame: One year (from baseline to 1-year post-treatment)]
Quality of Life Assessment of Growth Hormone Deficiency in Adults [Time Frame: One year (from baseline to 1-year post-treatment)]
Change in Physical function- Maximum grip strength [Time Frame: One year (from baseline to 1-year post-treatment)]
Change in Physical function-DEXA measure [Time Frame: One year (from baseline to 1-year post-treatment)]
Secondary ID(s)
UTN: U1111-1201-5972
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Novo Nordisk A/S
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey